<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828646</url>
  </required_header>
  <id_info>
    <org_study_id>CN156-012</org_study_id>
    <nct_id>NCT00828646</nct_id>
  </id_info>
  <brief_title>Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese</brief_title>
  <acronym>JMAD</acronym>
  <official_title>Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Japanese Subjects and a Comparison to Healthy Elderly Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics,
      and pharmacodynamics following 14-day multiple oral doses BMS-708163 in healthy young male
      Japanese and healthy elderly male and female Japanese subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Within 30 days after the follow-up evaluation on Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BMS-708163 - Panel 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Age 20-45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-708163 - Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Age 20-45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-708163 - Panel 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(age 65 or above)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-708163 - Panel 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(age 65 or above)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163</intervention_name>
    <description>Capsules, Oral, 50 mg, once daily, 14 days</description>
    <arm_group_label>BMS-708163 - Panel 1</arm_group_label>
    <arm_group_label>BMS-708163 - Panel 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163</intervention_name>
    <description>Capsules, Oral, 100 mg/day, once daily, 14 days</description>
    <arm_group_label>BMS-708163 - Panel 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163</intervention_name>
    <description>Capsules, Oral, 75 or 100 mg/day, once daily, 14 days</description>
    <arm_group_label>BMS-708163 - Panel 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules, Oral, once daily, 14 days</description>
    <arm_group_label>BMS-708163 - Panel 1</arm_group_label>
    <arm_group_label>BMS-708163 - Panel 2</arm_group_label>
    <arm_group_label>BMS-708163 - Panel 3</arm_group_label>
    <arm_group_label>BMS-708163 - Panel 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations

          -  Body Mass Index (BMI) of 19 to 25 kg/m2, inclusive. BMI = weight (kg)/ [height (m)]2

          -  Men, ages 20 to 45, and men and women [not of childbearing potential (i.e., who are
             postmenopausal or surgically sterile)], ages 65 or older. Women are considered
             surgically sterile only if they have undergone a hysterectomy, bilateral tubal
             ligation, or bilateral oophorectomy. Women are considered postmenopausal only if they
             have had amenorrhea for ≥12 consecutive months, or for women on hormone replacement
             therapy (HRT), if they have a documented serum follicle stimulating hormone (FSH)
             level &gt; 35 mIU/mL

        Exclusion Criteria:

          -  WOCBP

          -  Women who are pregnant or breastfeeding

          -  Women with a positive pregnancy test on enrollment or prior to administration of
             investigational product

          -  Sexually active fertile men not using effective birth control if their partners are
             WOCBP

          -  Any significant acute or chronic medical illness

          -  Any current or recent? medical history of gastrointestinal disease that may affect
             evaluation of study treatment

          -  History of recent major surgery or gastrointestinal surgery that may impact on
             evaluation or absorption of study drug

          -  History of blood donation or blood transfusion within 4 weeks prior to the study
             treatment

          -  Intolerance to oral medication or venous access

          -  QTc interval (Bazett's correction) &gt;500 ms at screening

          -  Smoking more than 10 cigarettes per day

          -  Recent (within 6 months) drug or alcohol abuse as defined in DSM IV

          -  Any other sound medical, psychiatric and/or social reason as determined by the
             investigator

          -  Subjects ≥ 65 yr are allowed to have age-related minimum or mild abnormalities in
             vital sign (i.e. blood pressure) or laboratory tests (i.e. blood sugar, serum
             cholesterol, or serum triglyceride) as far as they are not deemed signs or
             consequences of illness or organ dysfunction and a subject of medical treatment

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations

          -  Positive urine screen for drugs of abuse

          -  Positive blood screen for hepatitis C antibody, or HIV or hepatitis B antigen

          -  Indicators of abnormal renal function at baseline: any urine protein

          -  History of allergy to Gamma-Secretase Inhibitor or related compounds

          -  History of any significant drug allergy

          -  Prior exposure to BMS-708163

          -  Exposure to any investigational drug or placebo within 4 weeks of study drug
             administration

          -  Use of any prescription drugs or over-the-counter acid controllers within 4 weeks
             prior to study drug administration

          -  Use of any other drugs, including over-the-counter medications and herbal
             preparations, within 2 weeks prior to study drug administration

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (eg, infectious disease) illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>2320064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>January 6, 2011</last_update_submitted>
  <last_update_submitted_qc>January 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

